Latest Breaking News On - Targeted augmentation - Page 13 : comparemela.com

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

– Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug – – 70.6% of patients treated with STK-001. | December 3, 2021

United kingdomUnited statesElaine wirrellHelen crossBarry tichoColin robertsAnn roberth lurieLinda lauxInternational league against epilepsyAmerican epilepsy societyBiomarker development at stoke therapeuticsAugmentation of nuclear gene outputStoke therapeutics incNorthwestern university feinberg school of medicineAugmentation of nuclear gene output is stokeBayley scales of infant development

Stoke Reports Early Efficacy Signals from Dravet Syndrome Study

Stoke Reports Early Efficacy Signals from Dravet Syndrome Study
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesBarry tichoAmerican epilepsy societyAugmentation of nuclear gene outputStoke therapeuticsTargeted augmentationNuclear gene output

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

Press release content from Business Wire. The AP news staff was not involved in its creation.

United kingdomUnited statesEric rojasAugmentation of nuclear gene outputCredit suisseCompany on twitter at stoketxStoke therapeutics incAnnual healthcare conferenceHealthcare conferenceTargeted augmentationNuclear gene outputStoke investorStoke therapeuticsBusiness wire

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates May 10, 2021 GMT BEDFORD, Mass. (BUSINESS WIRE) May 10, 2021 Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2021 and provided business updates. “The momentum we are seeing with STK-001 in the clinic is driven by high levels of interest from the Dravet community and our shared sense of urgency to advance a potential disease-modifying approach for the treatment of this devastating disease. The single dose portion of our Phase 1/2a MONARCH study in the U.S. is now fully enrolled up to the 30mg dose level and based on our progress, we now anticipate our first data readout from this single dose portion

United statesBorough of bedfordUnited kingdomEdwardm kayeEric rojasAugmentation of nuclear gene outputStoke therapeutics incRegulatory agencyExchange commissionAugmentation of nuclear gene output is stokeAmerican society of geneCompany on twitter at stoketxAssociation for researchChief executive officerClinical trial applicationUnited kingdom medicines

Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates

Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates March 9, 2021 GMT BEDFORD, Mass. (BUSINESS WIRE) Mar 9, 2021 Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2020 and provided business updates. “During the last year, the power and potential of RNA medicines became clear to the world. Simultaneously, the Stoke team advanced our efforts to discover and develop RNA-based medicines that aim to address the underlying cause of severe genetic diseases by selectively boosting protein production,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Our Phase 1/2a MONARCH study in children and adolescents with Dravet

United statesUnited kingdomEdwardm kayeAmerican epilepsy societyAugmentation of nuclear gene outputStoke therapeutics incExchange commissionAugmentation of nuclear gene output is stokeHead of corporate affairsChief executive officerTargeted augmentationNuclear gene outputClinical studyAutosomal dominant optic atrophyPrivate securities litigation reform actRisk factors